Mystery of the brain metastatic disease in breast cancer patients: Improved patient stratification, disease prediction and targeted prevention on the horizon?

EPMA Journal

Volumn 8, Issue 2, 2017, Pages 119-127

  Polivka, Jiri ^a,b   Kralickova, Milena ^a   Kaiser, Christina ^c   Kuhn, Walther ^c   Golubnitschaja, Olga ^c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Faculty Hospital Plzen   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

Brain metastasis; Breast cancer; Multilevel diagnostics; Patient stratification; Predictive preventive and personalised medicine; Risk factors

Indexed keywords

2 AMINOBUTYRIC ACID; ALPHA CRYSTALLIN; ALPHA2 6 SIALYLTRANSFERASE; ANGIOGENIC FACTOR; ANGIOPOIETIN 2; ATAXIN 1; CAPECITABINE; CHEMOKINE RECEPTOR CCR4; CYCLOOXYGENASE 2; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; HORMONE RECEPTOR; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MONOCLONAL ANTIBODY; PERTUZUMAB; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROGESTERONE RECEPTOR; RAD51 PROTEIN; TRANSFERASE; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG; VASCULOTROPIN;

AGE; BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; BREAST CANCER MOLECULAR SUBTYPE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PREVENTION; CANCER RISK; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DISEASE PREDISPOSITION; FATALITY; GENETIC MARKER; HISTOPATHOLOGY; HORMONE BLOOD LEVEL; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IMMUNE DYSREGULATION; INTRADUCTAL CARCINOMA; LOBULAR CARCINOMA IN SITU; MOLECULARLY TARGETED THERAPY; MOTIVATION; PREDICTION; PREMENOPAUSE; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

EID: 85016138178     PISSN: 18785077     EISSN: 18785085     Source Type: Journal    
DOI: 10.1007/s13167-017-0087-5     Document Type: Review

References (71)

1. Golubnitschaja O, Debald M, Yeghiazaryan K, Kuhn W, Pešta M, Costigliola V, et al. Breast cancer epidemic in the early twenty-first century: evaluation of risk factors, cumulative questionnaires and recommendations for preventive measures. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2016;37:12941-57.
2. Darlix A, Zouaoui S, Rigau V, Bessaoud F, Figarella-Branger D, Mathieu-Daudé H, et al. Epidemiology for primary brain tumors: a nationwide population-based study. J Neurooncol. 2016.
3. Polivka J, Polivka J, Rohan V, Topolcan O. New treatment paradigm for patients with anaplastic oligodendroglial tumors. Anticancer Res. 2014;34:1587-94.
4. Polivka J, Polivka Jr J, Rohan V, Topolcan O. Glioblastoma multiforme-a review of pathogenesis, biomarkers and therapeutic perspectives. Cesk Slov Neurol N. 2013;76(109):575-83.
5. Polivka J, Polivka J, Holubec L, Kubikova T, Priban V, Hes O, et al. Advances in experimental targeted therapy and immunotherapy for patients with glioblastoma multiforme. Anticancer Res. 2017;37:21-33.
6. Lin NU, Bellon JR, Winer EP. CNS metastases in breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2004;22:3608-17.
7. Chang EL, Lo S. Diagnosis and management of central nervous system metastases from breast cancer. Oncologist. 2003;8:398-410.
8. Hung M-H, Liu C-Y, Shiau C-Y, Hsu C-Y, Tsai Y-F, Wang Y-L, et al. Effect of age and biological subtype on the risk and timing of brain metastasis in breast cancer patients. PLoS One. 2014;9:e89389.
9. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, et al. Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol Off J Eur Soc Med Oncol. 2006;17:935-44.
10. Tham Y-L, Sexton K, Kramer R, Hilsenbeck S, Elledge R. Primary breast cancer phenotypes associated with propensity for central nervous system metastases. Cancer. 2006;107:696-704.
11. Heitz F, Rochon J, Harter P, Lueck H-J, Fisseler-Eckhoff A, Barinoff J, et al. Cerebral metastases in metastatic breast cancer: disease-specific risk factors and survival. Ann Oncol Off J Eur Soc Med Oncol. 2011;22:1571-81.
12. Graesslin O, Abdulkarim BS, Coutant C, Huguet F, Gabos Z, Hsu L, et al. Nomogram to predict subsequent brain metastasis in patients with metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:2032-7.
13. Hicks DG, Short SM, Prescott NL, Tarr SM, Coleman KA, Yoder BJ, et al. Breast cancers with brain metastases are more likely to be estrogen receptor negative, express the basal cytokeratin CK5/6, and overexpress HER2 or EGFR. Am J Surg Pathol. 2006;30:1097-104.
14. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, Luo X, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:419-25.
15. Chow L, Suen D, Ma KK, Kwong A. Identifying risk factors for brain metastasis in breast cancer patients: implication for a vigorous surveillance program. Asian J Surg. 2015;38:220-3.
16. Heitz F1, Harter P, Lueck HJ, Fissler-Eckhoff A, Lorenz-Salehi F, Scheil-Bertram S, et al. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases. Eur J Cancer. 2009;45(16):2792-8. doi: 10.1016/j.ejca.2009.06.027.
17. Prevention of breast cancers summary | European Cancer Prevention [Internet]. [cited 2016 Dec 30]. Available from: http://ecpo.org/?page_id=522
18. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747-52.
19. Network CGA. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
20. Makki J. Diversity of breast carcinoma: histological subtypes and clinical relevance. Clin Med Insights Pathol. 2015;8:23-31.
21. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28:3271-7.
22. Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JGM, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008;68:3108-14.
23. Soni A, Ren Z, Hameed O, Chanda D, Morgan CJ, Siegal GP, et al. Breast cancer subtypes predispose the site of distant metastases. Am J Clin Pathol. 2015;143:471-8.
24. Ishihara M, Mukai H, Nagai S, Onozawa M, Nihei K, Shimada T, et al. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival. Oncology. 2013;84:135-40.
25. Tonyali O, Coskun U, Yuksel S, Inanc M, Bal O, Akman T, et al. Risk factors for brain metastasis as a first site of disease recurrence in patients with HER2 positive early stage breast cancer treated with adjuvant trastuzumab. Breast Edinb Scotl. 2016;25:22-6.
26. Leone JP, Leone BA. Breast cancer brain metastases: the last frontier. Exp Hematol Oncol. 2015;4:33.
27. Venur VA, Leone JP. Targeted therapies for brain metastases from breast cancer. Int J Mol Sci. 2016;17.
28. Witzel I, Oliveira-Ferrer L, Pantel K, Müller V, Wikman H. Breast cancer brain metastases: biology and new clinical perspectives. Breast Cancer Res BCR. 2016;18:8.
29. Polivka J, Pesta M, Janku F. Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? Expert Rev Mol Diagn. 2015;15:1631-44.
30. Sosińska-Mielcarek K, Duchnowska R, Winczura P, Badzio A, Majewska H, Lakomy J, et al. Immunohistochemical prediction of brain metastases in patients with advanced breast cancer: the role of Rad51. Breast Edinb Scotl. 2013;22:1178-83.
31. Sihto H, Lundin J, Lundin M, Lehtimäki T, Ristimäki A, Holli K, et al. Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res BCR. 2011;13:R87.
32. Malin D, Strekalova E, Petrovic V, Deal AM, Al Ahmad A, Adamo B, et al. αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20:56-67.
33. Voduc KD, Nielsen TO, Perou CM, Harrell JC, Fan C, Kennecke H, et al. αB-crystallin expression in breast cancer is associated with brain metastasis. NPJ Breast Cancer. 2015;1.
34. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, Blackwell KL, et al. Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res BCR. 2011;13:R125.
35. Sirkisoon SR, Carpenter RL, Rimkus T, Miller L, Metheny-Barlow L, Lo H-W. EGFR and HER2 signaling in breast cancer brain metastasis. Front Biosci Elite Ed. 2016;8:245-63.
36. Da Silva L, Simpson PT, Smart CE, Cocciardi S, Waddell N, Lane A, et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res BCR. 2010;12:R46.
37. Berghoff AS, Bartsch R, Preusser M, Ricken G, Steger GG, Bago-Horvath Z, et al. Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. Breast Edinb Scotl. 2014;23:637-43.
38. Nam D-H, Jeon H-M, Kim S, Kim MH, Lee Y-J, Lee MS, et al. Activation of notch signaling in a xenograft model of brain metastasis. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:4059-66.
39. McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, et al. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol Cancer Res MCR. 2011;9:834-44.
40. Lee T-H, Avraham HK, Jiang S, Avraham S. Vascular endothelial growth factor modulates the transendothelial migration of MDA-MB-231 breast cancer cells through regulation of brain microvascular endothelial cell permeability. J Biol Chem. 2003;278:5277-84.
41. Avraham HK, Jiang S, Fu Y, Nakshatri H, Ovadia H, Avraham S. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. J Pathol. 2014;232:369-81.
42. Lee B-C, Lee T-H, Avraham S, Avraham HK. Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1alpha in breast cancer cell migration through human brain microvascular endothelial cells. Mol Cancer Res MCR. 2004;2:327-38.
43. Xu C, Zhao H, Chen H, Yao Q. CXCR4 in breast cancer: oncogenic role and therapeutic targeting. Drug Des Devel Ther. 2015;9:4953-64.
44. Wrobel JK, Toborek M. Blood-brain barrier remodeling during brain metastasis formation. Mol Med Camb Mass. 2016.
45. Kim LS, Huang S, Lu W, Lev DC, Price JE. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin Exp Metastasis. 2004;21:107-18.
46. Cox TR, Rumney RMH, Schoof EM, Perryman L, Høye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522:106-10.
47. Neman J, Termini J, Wilczynski S, Vaidehi N, Choy C, Kowolik CM, et al. Human breast cancer metastases to the brain display GABAergic properties in the neural niche. Proc Natl Acad Sci U S A. 2014;111:984-9.
48. Van Swearingen AE, Siegel MB, Anders CK. Breast cancer brain metastases: evidence for neuronal-like adaptation in a "breast-to-brain" transition? Breast Cancer Res BCR. 2014;16:304.
49. Termini J, Neman J, Jandial R. Role of the neural niche in brain metastatic cancer. Cancer Res. 2014;74:4011-5.
50. Pukrop T, Dehghani F, Chuang H-N, Lohaus R, Bayanga K, Heermann S, et al. Microglia promote colonization of brain tissue by breast cancer cells in a Wnt-dependent way. Glia. 2010;58:1477-89.
51. Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, et al. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin Exp Metastasis. 2008;25:799-810.
52. Neman J, Choy C, Kowolik CM, Anderson A, Duenas VJ, Waliany S, et al. Co-evolution of breast-to-brain metastasis and neural progenitor cells. Clin Exp Metastasis. 2013;30:753-68.
53. Bos PD, Zhang XH-F, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005-9.
54. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature. 2005;436:518-24.
55. Harrell JC, Prat A, Parker JS, Fan C, He X, Carey L, et al. Genomic analysis identifies unique signatures predictive of brain, lung, and liver relapse. Breast Cancer Res Treat. 2012;132:523-35.
56. Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, et al. Genomic characterization of brain metastases reveals branched evolution and potential therapeutic targets. Cancer Discov. 2015;5:1164-77.
57. Salhia B, Kiefer J, Ross JTD, Metapally R, Martinez RA, Johnson KN, et al. Integrated genomic and epigenomic analysis of breast cancer brain metastasis. PLoS One. 2014;9, e85448.
58. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol Off J Eur Soc Med Oncol. 2013;24:1526-33.
59. Bria E, Cuppone F, Fornier M, Nisticò C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231-9.
60. Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer. 2007;7:153.
61. Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist. 2008;13:620-30.
62. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14:244-8.
63. Swain SM, Kim S-B, Cortés J, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2013;14:461-71.
64. Swain SM, Baselga J, Miles D, Im Y-H, Quah C, Lee LF, et al. Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA. Ann Oncol Off J Eur Soc Med Oncol. 2014;25:1116-21.
65. Pivot X, Manikhas A, Zurawski B, Chmielowska E, Karaszewska B, Allerton R, et al. CEREBEL (EGF111438): a phase III, randomized, open-label study of lapatinib plus capecitabine versus trastuzumab plus capecitabine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:1564-73.
66. Tayyeb B, Parvin M. Pathogenesis of breast cancer metastasis to brain: a comprehensive approach to the signaling network. Mol Neurobiol. 2016;53:446-54.
67. Vanharanta S. A hypoxic ticket to the bone metastatic niche. Breast Cancer Res BCR. 2015;17:122.
68. Golubnitschaja O, Debald M, Kuhn W, Yeghiazaryan K, Bubnov RV, Goncharenko VM, et al. Flammer syndrome and potential formation of pre-metastatic niches: a multi-centred study on phenotyping, patient stratification, prediction and potential prevention of aggressive breast cancer and metastatic disease. EPMA J. 2016;7:A25.
69. Marko NF, Xu Z, Gao T, Kattan MW, Weil RJ. Predicting survival in women with breast cancer and brain metastasis: a nomogram outperforms current survival prediction models. Cancer. 2012;118:3749-57.
70. Subbiah IM, Lei X, Weinberg JS, Sulman EP, Chavez-MacGregor M, Tripathy D, et al. Validation and development of a modified breast graded prognostic assessment as a tool for survival in patients with breast cancer and brain metastases. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:2239-45.
71. Barnholtz-Sloan JS, Yu C, Sloan AE, Vengoechea J, Wang M, Dignam JJ, et al. A nomogram for individualized estimation of survival among patients with brain metastasis. Neuro-Oncology. 2012;14:910-8.